Ca
Non vérifié

CatalYm

Ce que nous écrivons

BiotechnologieIndustrie pharmaceutiqueMédecine - DiversOncologieSanté
24/10/2026
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
Biotechnologie
Expos
Industrie
CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026
Source
1.00
06/10/2026
Événements
Industrie
Science
Médecine - Divers
Biotechnologie
Santé Publique
Santé
Industrie pharmaceutique
Oncologie
CatalYm to Present Updated GDFATHER-NEO Clinical Data and Highlight Ongoing Phase 2b Visugromab Trials at ESMO 2026
Source
1.00
09/06/2026
Marché du travail
Science
Médecine - Divers
Biotechnologie
Santé Publique
Santé
Industrie pharmaceutique
Oncologie
CatalYm Appoints Peter Garcia as Chief Financial Officer
Source
1.00
02/12/2025
Industrie
Science
Médecine - Divers
Biotechnologie
Santé Publique
Santé
Industrie pharmaceutique
Oncologie
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC
Source
1.00
17/10/2025
Oncologie
Santé
Biotechnologie
Santé Publique
Médecine - Divers
Industrie pharmaceutique
Événements
Expos
Industrie
CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO
Source
1.00
30/09/2025
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé
Médecine - Divers
Industrie
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC
Source
1.00
30/09/2025
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé
Médecine - Divers
Industrie
CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC
Source
1.00
22/09/2025
Expos
Industrie
Oncologie
Santé
Médecine - Divers
Science
Industrie pharmaceutique
CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial in Late-breaking Oral Presentation at ESMO
Source
1.00
09/01/2025
Marché du travail
Science
Biotechnologie
Industrie pharmaceutique
Oncologie
Santé
Médecine - Divers
CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab
Source
1.00

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0